Elan Ezickson Net Worth

The estimated Net Worth of Elan Ezickson is at least $859 Thousand dollars as of 6 February 2023. Mr. Ezickson owns over 750 units of Alaunos Therapeutics Inc stock worth over $4,872 and over the last 15 years he sold ZIOP stock worth over $641,206. In addition, he makes $212,562 as Independent Director at Alaunos Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Ezickson ZIOP stock SEC Form 4 insiders trading

Elan has made over 7 trades of the Alaunos Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 750 units of ZIOP stock worth $4,920 on 6 February 2023.

The largest trade he's ever made was selling 10,000 units of Alaunos Therapeutics Inc stock on 10 June 2011 worth over $187,300. On average, Elan trades about 1,620 units every 174 days since 2010. As of 6 February 2023 he still owns at least 5,600 units of Alaunos Therapeutics Inc stock.

You can see the complete history of Mr. Ezickson stock trades at the bottom of the page.

Elan Ezickson biography

Elan Z. Ezickson J.D. serves as Independent Director of the Company. Mr. Ezickson has served as a member of our board since September 2018. Mr. Ezickson served as Chief Operating Officer & Head of Corporate Development for Scholar Rock Holding Corporation from August 2014 until his retirement in December 2018. Prior to Scholar Rock, Mr. Ezickson served as Executive Vice President and Chief Operating Officer of Aveo Pharmaceuticals, Inc., where he worked from 2003 to July 2013. Previously, Mr. Ezickson worked at Biogen Inc. in roles of increasing responsibility, including serving as the President of Biogen Canada, Program Executive and Associate General Counsel. Since December 2019, Mr. Ezickson has served on the board of directors of Marinus Pharmaceuticals, Inc., a publicly-held company focused on developing and commercializing innovative therapeutics to treat patients suffering from rare seizure disorders. Mr. Ezickson holds a B.A. in Political Science from Yale University and a J.D. from the Columbia University School of Law. The board believes that Mr. Ezickson’s deep operating and management experience at several leading life science companies, as well as his legal expertise and operational experience, qualifies him to serve on the board.

What is the salary of Elan Ezickson?

As the Independent Director of Alaunos Therapeutics Inc, the total compensation of Elan Ezickson at Alaunos Therapeutics Inc is $212,562. There are 9 executives at Alaunos Therapeutics Inc getting paid more, with Laurence Cooper having the highest compensation of $3,317,570.

How old is Elan Ezickson?

Elan Ezickson is 56, he's been the Independent Director of Alaunos Therapeutics Inc since 2018. There are 7 older and 10 younger executives at Alaunos Therapeutics Inc. The oldest executive at Alaunos Therapeutics Inc is J. Kevin Buchi, 65, who is the Director.

What's Elan Ezickson's mailing address?

Elan's mailing address filed with the SEC is 5 RADNOR CORPORATE CENTER, SUITE 500, 100 MATSONFORD RD, RADNOR, PA, 19087.

Insiders trading at Alaunos Therapeutics Inc

Over the last 19 years, insiders at Alaunos Therapeutics Inc have traded over $2,792,771 worth of Alaunos Therapeutics Inc stock and bought 7,941,160 units worth $39,823,909 . The most active insiders traders include Randal J Kirk, Randal Jintrexon Corp Kirk, and Lindsay A Md Rosenwald. On average, Alaunos Therapeutics Inc executives and independent directors trade stock every 72 days with the average trade being worth of $152,086. The most recent stock trade was executed by Groot Eleanor De on 22 December 2021, trading 20,132 units of ZIOP stock currently worth $25,568.

What does Alaunos Therapeutics Inc do?

Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.

Complete history of Mr. Ezickson stock trades at AVEO Pharmaceuticals Inc, Marinus Pharmaceuticals Inc, Alaunos Therapeutics Inc, and Scholar Rock Corp

Alaunos Therapeutics Inc executives and stock owners

Alaunos Therapeutics Inc executives and other stock owners filed with the SEC include:

• Laurence Cooper,
  Chief Executive Officer, Director
• Satyavrat Shukla,
  Chief Financial Officer
• Robert Hadfield,
  Executive Vice President, Chief Compliance Officer, General Counsel, Secretary
• Kevin Lafond,
  Senior Vice President - Finance, Chief Accounting Officer, Treasurer
• Heidi Hagen,
  Independent Director
• Dr. Eleanor de Groot Ph.D.,
  Exec. VP of Operations
• Christopher Bowden,
  Independent Director
• Scott Tarriff,
  Independent Chairman of the Board
• Dr. Raffaele Baffa M.D., Ph.D.,
  Chief Medical Officer and Exec. VP of R&D
• Elan Ezickson,
  Independent Director
• Zuie-Chin Huang M.B.A.,
  Exec. Chairman
• Mary Thistle,
  Independent Director
• Raffaele Baffa,
  Chief Medical Officer
• Christopher Taylor,
  Vice President, Investor Relations and Corporate Communications
• James Huang,
  Director
• J. Kevin Buchi,
  Director
• Lynn Ferrucci,
  Executive Vice President of Human Resources, Facilities, Administration and IT
• Eleanor De Groot,
  Executive Vice President, General Manager, Cell Therapy
• Jill Buck,
  Executive Vice President, General Manager, Gene Therapy
• Dr. Drew Deniger,
  Head of TCR-T Cell Therapy Program
• Dr. David M. Mauney M.D.,
  Consultant
• Melinda Lackey,
  Sr. VP of Legal
• Michael Wong,
  VP of Fin. & Principal Accounting Officer
• Timothy M. Cunningham CPA, M.B.A.,
  Interim CFO & Principal Financial Officer
• Kevin S. Boyle Sr.,
  CEO & Director
• James Anthony Cannon,
  Director
• Randal Jintrexon Corp Kirk,
  
• Murray Brennan,
  Director
• Wyche Fowler,
  Director
• Randal J Kirk,
  Director
• Caesar J Belbel,
  COO, CLO, and Secretary
• Michael Weiser,
  Director
• Francois Lebel,
  Executive Vice President R&D
• David M Md Mauney,
  President
• Douglas W. Pagan,
  Director
• Scott Braunstein,
  Director
• Hagop Youssoufian,
  Executive VP, CMO
• Timothy Mcinerney,
  Director
• Jonathan Lewis,
  CEO
• Jason Amello,
  Executive Vice President & CFO
• Richard E Bagley,
  President, COO & Treasurer
• George B Abercrombie,
  Director
• Robert Peter Gale,
  Senior V.P. of Research
• Lindsay A Md Rosenwald,
  10% owner
• Woodlands Health Ventures F...,
  10% owner
• Gary S Fragin,
  Director
• Sath Shukla,
  EVP, Chief Financial Officer
• Jaime Vieser,
  Director
• Holger Weis,
  Director
• Robert W Postma,
  Director
• Kevin S. Sr. Boyle,
  Chief Executive Officer
• Melinda Lackey,
  Senior Vice President, Legal